8-K: Exicure Faces Nasdaq Delisting Threat Due to Late 10-K Filing

Exicure, Inc. received a Nasdaq notice of non-compliance for failing to file its annual report, putting its listing status at risk.

Summary

• Exicure, Inc. received a notification from Nasdaq on April 17, 2024, stating the company is not compliant with listing rules due to the late filing of its Form 10-K for the year ended December 31, 2023.
• This non-compliance is a result of not meeting Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the SEC.
• The company was previously granted an exception until May 20, 2024, to file its Form 10-Q for the quarter ended September 30, 2023.
• Any further extensions for both the Form 10-Q and the Form 10-K are limited to May 20, 2024.
• Exicure's management is working to complete the Form 10-K and intends to file it as soon as possible to regain compliance.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the non-compliance notice from Nasdaq and the risk of delisting. While the company is working to rectify the situation, the uncertainty and potential negative consequences weigh heavily on the outlook.

Positives

• Exicure's management is actively working to complete the Form 10-K.
• The company intends to file the Form 10-K as soon as practicable to regain compliance with Nasdaq listing rules.

Negatives

• Exicure is not in compliance with Nasdaq listing rules due to the late filing of its Form 10-K.
• The company has received a delinquency notice from Nasdaq.
• The company faces a potential delisting if it does not file the required reports by May 20, 2024.

Risks

• Exicure faces the risk of delisting from Nasdaq if it fails to file its Form 10-K and Form 10-Q by May 20, 2024.
• The company's reputation and investor confidence could be negatively impacted by the non-compliance.
• The company's ability to raise capital may be hindered due to the delisting risk.

Future Outlook

Exicure is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly.

Management Comments

• The company's management is working diligently to complete the Form 10-K.
• Exicure intends to file the Form 10-K as soon as practicable to regain compliance with the Nasdaq Listing Rule.

Industry Context

This announcement highlights the importance of timely financial reporting for publicly listed companies and the potential consequences of non-compliance with exchange listing rules. It is not uncommon for companies to face delisting threats due to late filings, especially during periods of restructuring or financial difficulty.

Comparison to Industry Standards

• Many biotechnology companies face challenges in meeting financial reporting deadlines, especially during restructuring phases.
• Companies like Agenus Inc. and Cellectar Biosciences have also faced similar issues with Nasdaq compliance, highlighting the industry-wide pressure to maintain timely filings.
• The May 20th deadline is a common timeframe given by Nasdaq for companies to rectify filing deficiencies, and Exicure's situation is not unique in this regard.

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment value.
• Employees may experience uncertainty regarding the company's future.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• Exicure must file its Form 10-K for the year ended December 31, 2023, and its Form 10-Q for the quarter ended September 30, 2023, by May 20, 2024.
• The company will continue to explore strategic alternatives to maximize stockholder value.

Key Dates

Keywords

Nasdaq, delisting, non-compliance, Form 10-K, Form 10-Q, financial reporting, SEC, compliance, XCUR